HCV Routes of Transmission: What Goes Around Comes Around

Miriam J. Alter

doi:10.1055/s-0031-1297923

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis 2011; 31(4): 340-346
DOI: 10.1055/s-0031-1297923

HCV Routes of Transmission: What Goes Around Comes Around

Miriam J. Alter¹

¹Division of Infectious Diseases, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas

Abstract

ABSTRACT

The widespread availability of injectable therapies and increase in illicit injection drug use were responsible for the rapid emergence of hepatitis C virus (HCV) infection in the latter half of the 20th century. Iatrogenic exposures and illicit injection drug use have been the predominant risk factors for HCV transmission worldwide. In developing countries, unsafe therapeutic injection practices appear to be responsible for most infections. In developed countries, donor testing has virtually eliminated transfusion-related infections, but infections transmitted to patients by unsafe injections practices is an emerging problem. Injection drug use is the major risk factor for HCV; incidence remains high among new injectors, and this behavior likely contributes to and/or confounds reported associations between HCV-positive persons and histories of noninjection drug use, tattooing, and incarceration. Increased use of illegal drugs also may play a role in the emergence of sexually transmitted HCV infections among HIV-positive men who have sex with men. Ongoing monitoring of the epidemiology of HCV infection is crucial for preventing future infections.

KEYWORDS

HCV - epidemiology - iatrogenic - drug use - sexual

Volltext

Referenzen

REFERENCES

1 Feinstone S M, Kapikian A Z, Purcell R H, Alter H J, Holland P V. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med. 1975; 292 (15) 767-770
2 Mosley J W, Redeker A G, Feinstone S M, Purcell R H. Mutliple hepatitis viruses in multiple attacks of acute viral hepatitis. N Engl J Med. 1977; 296 (2) 75-78
3 Aach R D, Kahn R A. Post-transfusion hepatitis: current perspectives. Ann Intern Med. 1980; 92 (4) 539-546
4 Tabor E, Snoy P, Gerety R J, Wickerhauser M, Menache D, Seeff L B. Transmission of agent of post-transfusion non-A, non-B hepatitis by cryoprecipitate prepared from plasma of symptomless chronic carrier. Lancet. 1983; 1 (8314-5) 63-64
5 Cossart Y E, Kirsch S, Ismay S L. Post-transfusion hepatitis in Australia. Report of the Australian Red Cross study. Lancet. 1982; 1 (8265) 208-213
6 Grillner L, Bergdahl S, Jyrälä A. Non-A, non-B hepatitis after open-heart surgery in Sweden. Scand J Infect Dis. 1982; 14 (3) 171-175
7 Meyers J D, Dienstag J L, Purcell R H, Thomas E D, Holmes K K. Parenterally transmitted non-A, non-B hepatitis: an epidemic reassessed. Ann Intern Med. 1977; 87 (1) 57-59
8 Alter M J, Gerety R J, Smallwood L A et al.. Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population. J Infect Dis. 1982; 145 (6) 886-893
9 Alter M J, Coleman P J, Alexander W J et al.. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA. 1989; 262 (9) 1201-1205
10 Choo Q L, Weiner A J, Overby L R, Kuo G, Houghton M, Bradley D W. Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. Br Med Bull. 1990; 46 (2) 423-441
11 Alter H J, Purcell R H, Shih J W et al.. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med. 1989; 321 (22) 1494-1500
12 Kuo G, Choo Q L, Alter H J et al.. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989; 244 (4902) 362-364
13 Alter M J, Margolis H S, Krawczynski K et al.. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992; 327 (27) 1899-1905
14 Seeff L B, Buskell-Bales Z, Wright E C et al.. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med. 1992; 327 (27) 1906-1911
15 Centers for Disease Control and Prevention . Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998; 47 (RR-19) 1-39
16 Alter M J. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007; 13 (17) 2436-2441
17 Busch M P, Glynn S A, Stramer S L NHLBI-REDS NAT Study Group et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion. 2005; 45 (2) 254-264
18 Hladik W, Kataaha P, Mermin J et al.. Prevalence and screening costs of hepatitis C virus among Ugandan blood donors. Trop Med Int Health. 2006; 11 (6) 951-954
19 Hauri A M, Armstrong G L, Hutin Y J. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS. 2004; 15 (1) 7-16
20 Frank C, Mohamed M K, Strickland G T et al.. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000; 355 (9207) 887-891
21 Perz J F, Thompson N D, Schaefer M K, Patel P R. US outbreak investigations highlight the need for safe injection practices and basic infection control. Clin Liver Dis. 2010; 14 (1) 137-151, x
22 Alter M J. Healthcare should not be a vehicle for transmission of hepatitis C virus. J Hepatol. 2008; 48 (1) 2-4
23 Centers for Disease Control and Prevention (CDC) . Transmission of hepatitis B and C viruses in outpatient settings—New York, Oklahoma, and Nebraska, 2000-2002. MMWR Morb Mortal Wkly Rep. 2003; 52 (38) 901-906
24 Desenclos J C, Bourdiol-Razès M, Rolin B et al.. Hepatitis C in a ward for cystic fibrosis and diabetic patients: possible transmission by spring-loaded finger-stick devices for self-monitoring of capillary blood glucose. Infect Control Hosp Epidemiol. 2001; 22 (11) 701-707
25 Krause G, Trepka M J, Whisenhunt R S et al.. Nosocomial transmission of hepatitis C virus associated with the use of multidose saline vials. Infect Control Hosp Epidemiol. 2003; 24 (2) 122-127
26 Germain J M, Carbonne A, Thiers V et al.. Patient-to-patient transmission of hepatitis C virus through the use of multidose vials during general anesthesia. Infect Control Hosp Epidemiol. 2005; 26 (9) 789-792
27 Thompson N D, Perz J F, Moorman A C, Holmberg S D. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008. Ann Intern Med. 2009; 150 (1) 33-39
28 Phillips L D. History of I.V. therapy. In: Davis F A, ed. Manual of I.V. Therapeutics. Philadelphia; 1993: 1-10
29 Des Jarlais D C, Diaz T, Perlis T et al.. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol. 2003; 157 (5) 467-471
30 Hagan H, Des Jarlais D C, Stern R et al.. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy. 2007; 18 (5) 341-351
31 Thorpe L E, Ouellet L, Hershow R, Bailey S, Williams I, Monerosso E. The multiperson use of non-syringe injection equipment and risk of hepatitis c infection in a cohort of young adult injection drug users, Chicago 1997–1999. Ann Epidemiol. 2000; 10 (7) 472-473
32 Thorpe L E, Ouellet L J, Hershow R et al.. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002; 155 (7) 645-653
33 Burt R D, Hagan H, Garfein R S, Sabin K, Weinbaum C, Thiede H. Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk behaviors, and preventive measures among Seattle injection drug users aged 18–30 years, 1994–2004. J Urban Health. 2007; 84 (3) 436-454
34 Hahn J A, Page-Shafer K, Lum P J et al.. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis. 2002; 186 (11) 1558-1564
35 Kamili S, Krawczynski K, McCaustland K, Li X, Alter M J. Infectivity of hepatitis C virus in plasma after drying and storing at room temperature. Infect Control Hosp Epidemiol. 2007; 28 (5) 519-524
36 Hagan H, Pouget E R, Des Jarlais D C. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011; 204 (1) 74-83
37 Terrault N A. Sexual activity as a risk factor for hepatitis C. Hepatology. 2002; 36 (5, Suppl 1) S99-S105
38 Tohme R A, Holmberg S D. Is sexual contact a major mode of hepatitis C virus transmission?. Hepatology. 2010; 52 (4) 1497-1505
39 Alter M J, Kruszon-Moran D, Nainan O V et al.. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999; 341 (8) 556-562
40 Hagan H, Snyder N, Hough E et al.. Case-reporting of acute hepatitis B and C among injection drug users. J Urban Health. 2002; 79 (4) 579-585
41 Robotin M C, Copland J, Tallis G et al.. Surveillance for newly acquired hepatitis C in Australia. J Gastroenterol Hepatol. 2004; 19 (3) 283-288
42 Spada E, Mele A, Ciccozzi M SEIEVA collaborating group et al. Changing epidemiology of parenterally transmitted viral hepatitis: results from the hepatitis surveillance system in Italy. Dig Liver Dis. 2001; 33 (9) 778-784
43 Alter M J, Hadler S C, Judson F N et al.. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA. 1990; 264 (17) 2231-2235
44 Williams I T, Bell B P, Kuhnert W, Alter M J. Incidence and transmission patterns of acute hepatitis C in the United States, 1982–2006. Arch Intern Med. 2011; 171 (3) 242-248
45 Armstrong G L, Alter M J, McQuillan G M, Margolis H S. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000; 31 (3) 777-782
46 Aach R D, Szmuness W, Mosley J W et al.. Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients: the transfusion-transmitted viruses study. N Engl J Med. 1981; 304 (17) 989-994
47 Alter H J, Holland P V. Indirect tests to detect the non-A, non-B hepatitis carrier state. Ann Intern Med. 1984; 101 (6) 859-861
48 Donahue J G, Muñoz A, Ness P M et al.. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med. 1992; 327 (6) 369-373
49 Busch M P, Glynn S A, Wright D J National Heart, Lung, Blood Institute Nucleic Acid Test Study Group* et al. Relative sensitivities of licensed nucleic acid amplification tests for detection of viremia in early human immunodeficiency virus and hepatitis C virus infection. Transfusion. 2005; 45 (12) 1853-1863
50 Kleinman S H, Stramer S L, Brodsky J P, Caglioti S, Busch M P. Integration of nucleic acid amplification test results into hepatitis C virus supplemental serologic testing algorithms: implications for donor counseling and revision of existing algorithms. Transfusion. 2006; 46 (5) 695-702
51 Sharma U K, Stramer S L, Wright D J Retrovirus Epidemiology Donor Study et al. Impact of changes in viral marker screening assays. Transfusion. 2003; 43 (2) 202-214
52 Zou S, Dorsey K A, Notari E P et al.. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion. 2010; 50 (7) 1495-1504
53 Zou S, Notari IV E P, Stramer S L, Wahab F, Musavi F, Dodd R Y. ARCNET Research Group . Patterns of age- and sex-specific prevalence of major blood-borne infections in United States blood donors, 1995 to 2002: American Red Cross blood donor study. Transfusion. 2004; 44 (11) 1640-1647
54 Armstrong G L. Injection drug users in the United States, 1979-2002: an aging population. Arch Intern Med. 2007; 167 (2) 166-173
55 Sun C A, Chen H C, Lu S N et al.. Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic risk factors. J Med Virol. 2001; 65 (1) 30-34
56 Okayama A, Stuver S O, Tabor E et al.. Incident hepatitis C virus infection in a community-based population in Japan. J Viral Hepat. 2002; 9 (1) 43-51
57 Fukuizumi K, Sata M, Suzuki H, Nakano H, Tanikawa K. Hepatitis C virus seroconversion rate in a hyperendemic area of HCV in Japan: a prospective study. Scand J Infect Dis. 1997; 29 (4) 345-347
58 Buffington J, Murray P J, Schlanger K et al.. Low prevalence of hepatitis C virus antibody in men who have sex with men who do not inject drugs. Public Health Rep. 2007; 122 (Suppl 2) 63-67
59 Urbanus A T, van de Laar T J, Stolte I G et al.. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS. 2009; 23 (12) F1-F7
60 Fierer D S, Factor S H, Uriel A J Centers for Disease Control and Prevention (CDC) et al. Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men—New York City, 2005-2010. MMWR Morb Mortal Wkly Rep. 2011; 60 (28) 945-950
61 van de Laar T J, Pybus O, Bruisten S et al.. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology. 2009; 136 (5) 1609-1617
62 van de Laar T J, Matthews G V, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS. 2010; 24 (12) 1799-1812
63 Taylor L E, Holubar M, Wu K et al.. Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials. Clin Infect Dis. 2011; 52 (6) 812-818
64 Spradling P R, Richardson J T, Buchacz K HIV Outpatient Study Investigators et al. Trends in hepatitis C virus infection among patients in the HIV Outpatient Study, 1996-2007. J Acquir Immune Defic Syndr. 2010; 53 (3) 388-396
65 Alter M J. Prevention of spread of hepatitis C. Hepatology. 2002; 36 (5, Suppl 1) S93-S98
66 Hwang L Y, Kramer J R, Troisi C et al.. Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population. Hepatology. 2006; 44 (2) 341-351
67 Arcari C M, Alter M J. Controversies in HCV transmission: from tattoos to barbershops. In: Hot Topics in Viral Hepatitis. FB Communications, Rome; 2008. 11: 19-27
68 Santayana G. Life of Reason, Reason in Common Sense. New York: Scribner's; 1905: 284. Available at: http://iat.iupui.edu/santayana/content/santayana-quotations Accessed October 5, 2011

Miriam J. AlterPh.D.

Professor, Department of Internal Medicine, Division of Infectious Diseases, University of Texas Medical Branch

301 University Blvd., Mail route 0435, Galveston, TX 77555-0435

eMail: mjalter@utmb.edu